However, GdCl 3 permanently destroys KCs by blocking K-type calcium channels (Paasz and Czekaj, 2000), thus unsuitable for clinical use
SURMOUNT-2, which included participants with type 2 diabetes, showed weight reductions of 12.8% to 15.7% with tirzepatide versus 3.2% with placebo
B.Pm, bone perimeter
Sikiric et al., 2003) or muscle (Staresinic et al., 2006) or tendon (Staresinic et al., 2003
Figure 2 provides an integrated overview of ASTs effects on pathological processes relevant to neurodegenerative diseases, including oxidative stress, neuroinflammation, and synaptic dysfunction, which are particularly relevant in AD and PD pathology
However, larger and long-term studies are warranted to generate more evidence